Cargill's $10 million gift to the U for a microbial and plant genomics building is a high-profile target for critics alleging the U is bowing to corporate influence.
Speaking after a groundbreaking for the building in early February, Cargill Senior Vice President Robbin Johnson said both organizations are sensitive to the issue.
"The university officials and Cargill were both concerned about that impression and were very explicit in making the grant and the university in accepting it, that it's a grant without strings attached. So I think in this case, I don't see a conflict of interest," Johnson said.
Even so, university President Mark Yudof agrees there is a risk that pressures from donors or to promote economic development can throw academic priorities out of joint.
"I don't think we're out of balance and I think we're trying to be very careful about that. I think some universities, without naming them, have made some mistakes in terms of giving up too much of their public purpose. I do think there's a danger. I do think the University of Minnesota is really very far from that," Yudof says.
Corporate funding is also prompting debate about research integrity. The prestigious international journal Nature recently published an editorial asking whether the university-industrial complex is out of control. While noting corporate relationships can bring many benefits to universities, the journal said the downside is increasingly clear, including evidence of biased research and undisclosed conflicts of interest.
Speaking from London, Nature Editor in Chief Philip Campbell says the stakes include public perception of university scientists as independent voices in the debate over controversial technologies.
"There is a risk that in some perhaps very prestigious universities, if action isn't taken about transparency, about the proper balance of funding, then some of the precious independence that these institutions have could be lost," said Campbell.
The Nature editorial cites one of the most controversial arrangements, a five-year $25 million deal between the University of California, Berkeley and the giant Swiss pharmaceutical and agricultural firm Novartis. The deal has raised concerns about preferential access. The company gained seats on the committee picking research projects, and has first dibs on some research results, even if paid for with public dollars.
At the University of Minnesota, some faculty members complain about excessive corporate influence. Others say the university is doing better than Berkeley, but worry about the trends.